Galera Therapeutics, Inc. 8-K

What Happened
Galera Therapeutics, Inc. announced that on May 15, 2026 it converted the remaining 42,839.11 shares of its Series B Non‑Voting Convertible Preferred Stock into 42,839,103 shares of common stock pursuant to the Series B Certificate of Designation. The company filed the Form 8‑K on May 19, 2026 and the report was signed by President and CEO J. Mel Sorensen.

Key Details

• 42,839.11 shares of Series B Preferred Stock were converted into 42,839,103 shares of common stock.
• No fractional common shares were issued; holders will receive cash for any fractional share amounts based on the trading value at close on the conversion date.
• Following the conversion, no shares of Series B Preferred Stock remain outstanding.
• Form 8‑K filed May 19, 2026; conversion effective May 15, 2026.

Why It Matters
The conversion issued 42,839,103 new common shares and eliminated the Series B preferred class, changing the company’s capital structure and increasing the count of common shares outstanding. For investors, that is a concrete change to the share base which can affect per‑share metrics (such as earnings per share) and ownership percentages — investors should review updated share counts and disclosures in subsequent filings.